TSH levels in pregnancy and links to mood, anxiety, and sexual function

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center, observational cross-sectional project collects maternal blood TSH measurements and psychometric scores during routine prenatal visits. Participants complete the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Arizona Sexual Experience Scale (ASEX), and the YKK-13 Quality of Life Scale and must have a TSH result from the past four weeks. Eligible women are aged 18–45 with a singleton pregnancy of at least six weeks, and those with prior psychiatric diagnoses, current thyroid treatment, multiple gestation, or major systemic disease are excluded. Data analysis will determine whether maternal TSH levels are associated with scores for depression, anxiety, sexual function, and overall quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Pregnant women aged 18-45 years

Singleton pregnancy

Gestational age ≥ 6 weeks

Literacy and ability to provide informed consent

Availability of a TSH result obtained within the past 4 weeks

Cognitive ability sufficient to complete the psychometric questionnaires (Beck Depression Inventory, Beck Anxiety Inventory, ASEX, and YKK-13 Quality of Life Scale)

Exclusion Criteria:

Multiple pregnancy

Previously diagnosed psychiatric disorder or active use of antidepressant/ anxiolytic medication

Current treatment for thyroid disease

History of thyroid surgery

Major systemic illness or significant obstetric complications

Age under 18 years or inability to provide informed consent

Inability to complete the questionnaires adequately (missing or invalid data)

Rationale:

Multiple pregnancies are excluded because they differ significantly from singleton pregnancies in terms of hormonal profile, obstetric risks, and psychological stress levels. This exclusion aims to ensure a homogeneous study population.

Where it's running

• SBÜ Gaziosmanpaşa Training and Research Hospital
  Istanbul, Gaziosmanpaşa, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: havva betül bacak, md — SBÜ Gaziosmanpaşa Training and Research Hospital
• Study coordinator: havva betül bacak, md
• Email: hbbacak90@gmail.com
• Phone: +905333610088

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjunctive JNJ-99245354 for Generalized Anxiety Disorder (GAD)

  This study tests whether adding JNJ-99245354 to existing GAD treatment helps reduce anxiety more than a placebo for adults with GAD who didn’t get adequate benefit from previous treatments.

  Recruiting at 4 sites Phase 3 Intra-Cellular Therapies, Inc. · Temecula, California and 3 other locations · NCT07856420

• Testing ITI-1284 for Generalized Anxiety Disorder (GAD)

  This phase 3 trial tests whether ITI-1284 is safe and tolerable when taken alone or with other medicines by adults with generalized anxiety disorder who haven’t responded to prior treatment.

  Recruiting at 3 sites Phase 3 Intra-Cellular Therapies, Inc. · Los Angeles, California and 2 other locations · NCT07807865

• Long-term safety and tolerability of SEP-363856 in adults with generalized anxiety disorder

  In adults with generalized anxiety disorder, this Phase 3 open-label extension tests whether continuing SEP-363856 at 50 mg or 75 mg daily for 26 weeks is safe, tolerable, and possibly helpful.

  Recruiting at 2 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Jacksonville, Florida and 1 other locations · NCT07786454

• Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety

  This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.

  Recruiting Ohio State University · Columbus, Ohio · NCT07774481

• Continuous Theta Burst Stimulation for Generalized Anxiety Disorder (cTBS for GAD)

  This study tests whether applying continuous theta burst stimulation to the right posterior parietal cortex or the right dorsolateral prefrontal cortex helps adults with generalized anxiety disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07770919

• Fixed-dose SEP-363856 vs placebo for adults with generalized anxiety disorder

  This trial tests whether a fixed 75 mg/day dose of SEP-363856 helps adults with generalized anxiety disorder more than placebo over 8 weeks.

  Recruiting at 11 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Redlands, California and 10 other locations · NCT07767903

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.